Preferential pulmonary retention of (S)-albuterol after inhalation of racemic albuterol

American Journal of Respiratory and Critical Care Medicine

Volumn 160, Issue 4, 1999, Pages 1136-1141

  Dhand, Rajiv ^a,b   Goode, Mark ^a   Reid, Ralston ^a   Fink, James B ^a   Fahey, Patrick J ^a   Tobin, Martin J ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b HINES VA HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SALBUTAMOL;

AREA UNDER THE CURVE; ARTICLE; BRONCHODILATATION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG METABOLISM; DRUG RETENTION; ENANTIOMER; FEMALE; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; METERED DOSE INHALER; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0032864737     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.160.4.9812074     Document Type: Article

References (35)

1. 2-agonist controversy. Drug Safety 11:260-283.
2. Jenne, J. W. 1996. Adverse effects of beta-adrenergic agonists. In A. R. Leff, editor. Pulmonary and Critical Care Pharmacology and Therapeutics. McGraw Hill, New York. 497-504.
3. Boulton, D. W., and J. P. Fawcett. 1996. Enantioselective disposition of albuterol in humans. Clin. Rev. Allergy Immunol. 14:115-138.
4. Morley, J. 1996. Anomalous effects of albuterol and other sympathomimetics in the guinea-pig. Clin. Rev. Allergy Immunol. 14:65-89.
5. Cockcroft, D. W., and V. A. Swystun. 1997. Effect of single doses of S-salbutamol, R-salbutamol, racemic salbutamol, and placebo on the airway response to methacholine. Thorax. 52:845-848.
6. Lipworth, B. J., D. J. Clark, P. Koch, and C. Arbeeny. 1997. Pharmacokinetics and extrapulmonary β-2 adrenoceptor activity of nebulised racemic salbutamol and its R and S isomers in healthy volunteers. Thorax 52:849-852.
7. Walle, U. K., G. R. Pesola, and T. Walle. 1993. Stereoselective sulphate conjugation of salbutamol in humans: comparison of hepatic, intestinal and platelet activity. Br. J. Clin. Pharmacal. 35:413-418.
8. Boulton, D. W., and J. P. Fawcett. 1995. Determination of salbutamol enantiomers in human plasma and urine by chiral high-performance liquid chromatography. J. Chromatog. B 672:103-109.
9. Boulton, D. W., and J. P. Fawcett. 1996. Enantioselective disposition of salbutamol in man following oral and intravenous administration. Br. J. Clin. Pharmacol. 41:35-40.
10. Boulton, D. W., and J. P. Fawcett. 1997. Pharmacokinetics and pharmacodynamics of single oral doses of albuterol and its enantiomers in humans. Clin. Pharmacol. Ther. 62:138-144.
11. Nelson, H. S., G. Bensch, W. W. Pleskow, R. DiSantostefano, S. DeGraw, D. S. Reasner, T. E. Rollons, and P. D. Robin. 1998. Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma. J. Allergy Clin. Immunol. 102:943-952.
12. Duarte, A. G., R. Dhand, K. Reid, J. B. Fink, P. J. Fahey, M. J. Tobin, and J. W. Jenne. 1996. Serum albuterol levels in mechanically ventilated patients and healthy subjects after metered dose inhaler administration. Am. J. Respir. Crit. Care Med. 154:1658-1663.
13. Hindle, M. H., and H. Chrystyn. 1992. Determination of the relative bioavailability of salbutamol to the lung following inhalation. Br. J. Clin. Pharmacol. 34:311-315.
14. Hindle, M., and H. Chrystyn. 1994. Relative bioavailability of salbutamol to the lung following inhalation using metered-dose inhalation and spacer devices. Thorax 49:549-553.
15. Newman, S. P., D. Pavia, F. Moren, N. F. Sheahan, and S. W. Clarke. 1981. Deposition of pressurized aerosols in the human respiratory tract. Thorax 36:52-55.
16. Dolovich, M., R. Ruffin, D. Corr, and M. T. Newhouse. 1983. Clinical evaluation of a simple demand inhalation MDI aerosol delivery device. Chest 84:36-41.
17. Lipworth, B. J., and D. J. Clark. 1998. Early lung absorption profile of non-CFC salbutamol via small and large volume plastic spacer devices. Br. J. Clin. Pharmacol. 46:45-48.
18. Rowland, M., and T. N. Tozer. 1995. Clinical Pharmacokinetics: Concepts and Applications, 3rd ed. Williams and Wilkins, Baltimore.
19. Tan, Y. K., and S. J. Soldin. 1987. Analysis of salbutamol enantiomers in human urine by chiral high-performance liquid chromatography and preliminary studies related to the stereoselective disposition kinetics in man. J. Chromatog. Biomed. Appl. 422:187-195.
20. Walters, E. H., A. Cockroft, T. Griffiths, K. Rocchiccioli, and B. H. Davies. 1981. Optimal dose of salbutamol respiratory solution: comparison of three doses with plasma levels. Thorax 36:625-628.
21. 2 activity of inhaled fenoterol and salbutamol in normal subjects. Thorax 48:656-658.
22. Lipworth, B. J., and D. J. Clark. 1998. Lung delivery of non-CFC salbutamol via small volume metal sparer and large volume plastic spacer devices compared with an open vent jet nebulizer. Br. J. Clin. Pharmacol 45:160-163.
23. Janson, C. 1991. Plasma levels and effects of salbutamol after inhaled or i.v. administration in stable asthma. Eur. Respir. J. 4:544-550.
24. Lipworth, B. J., R. A. Clark, D. P. Dhillon, T. A. Moreland, A. D. Struthers, G. A. Clark, and D. G. McDevitt. 1989. Pharmacokinetics, efficacy and adverse effects of sublingual salbutamol in patients with asthma. Eur. J. Clin. Pharmacol. 37:567-571.
25. Goldstein, D. A., Y. K. Tan, and S. J. Soldin. 1987. Pharmacokinetics and absolute bioavailability of salbutamol in healthy adult volunteers. Eur. J. Clin. Pharmacol. 32:631-634.
26. Anderson, P. J., X. Zhou, P. Breen, L. Gann, T. W. Logsdon, C. M. Compadre, and F. C. Hiller. 1998. Pharmacokinetics of (R,S)-albuterol after aerosol inhalation in healthy adult volunteers. J. Pharm. Sci. 87:841-844.
27. Morgan, D. J. 1990. Clinical pharmacokinetics of β-agonists. Clin. Pharmacokinet. 18:270-294.
28. Borgstrom, L., L. Nyberg, S. Jonsson, C. Lindberg, and J. Paulson. 1989. Pharmacokinetic evaluation in man of terbutaline given as separate enantiomers and as the racemate. Br. J. Clin. Pharmacol. 27:49-56.
29. Walle, T., J. G. Webb, E. E. Bagwell, U. K. Walle, H. B. Daniell, and T. E. Gaffney. 1988. Stereoscopic delivery and actions of beta receptor antagonists. Biochem. Pharmacol. 37:115-124.
30. Koike K., T. Horinouchi, and I. Takayanagi. 1994. Comparison of interactions of R(+)- and S(-)-isomers of β-adrenergic partial agonists, befunolol and carteolol, with high affinity site of β-adrenoceptors in the microsomal fractions from guinea-pig ciliary body, right atria and trachea. Gen. Pharmacol. 25:1477-1481.
31. Perrin-Fayolle, M. 1995. Salbutamol in the treatment of asthma. Lancet 346:1101.
32. Taylor, D. R., and M. R. Sears. 1994. Bronchodilators and bronchial hyperresponsiveness. Thorax 49:190.
33. Conolly, M. E., D. S. Davies, C. T. Dollery, and C. F. George. 1971. Resistance to β-adrenoceptor stimulants (a possible explanation for the rise in asthma deaths). Br. J. Pharmacol. 43:389-402.
34. Walle, T., and U. K. Walle. 1992. Stereoselective sulphate conjugation of 4-hydroxypropranolol and terbutaline by the human liver phenolsulfotransferases. Drug Metab. Dispos. 20:333-336.
35. 2-selective sympathomimetics. Pulmon. Pharmacol. 7:367-376.